First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    DexCom, Inc. (DXCM): the developments shaping its investment case

    Follow the evidence affecting DexCom, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research DexCom, Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-01
    MiniMed Group, Inc. Raises Fiscal Year 2027 Organic Revenue Growth Guidance
    Channel: Competitive dynamics and market share in the continuous glucose monitoring (CGM) market. Strong performance by a competitor could indicate a growing market but also increased competition.
    mixed· 1-3m
    2026-09-23
    Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide
    Channel: Increased adoption of GLP-1/GIP drugs for type 2 diabetes and obesity may lead to a larger population requiring continuous glucose monitoring (CGM) for better disease management and monitoring of treatment efficacy.
    Bullish· 1-5y
    2026-09-14
    Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.
    Channel: second_order_competitive_landscape
    watch· 3-12m

    Event impact log

    4 events mapped to DXCM since 2026-09-01. Evidence through 2026-09-23.

    DateEventChannelDirectionHorizonImpact
    2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial for EnicepatideIncreased adoption of GLP-1/GIP drugs for type 2 diabetes and obesity may lead to a larger population requiring continuous glucose monitoring (CGM) for better disease management and monitoring of treatment efficacy.Bullish1-5y0.30
    2026-09-14MiniMed Group, Inc. and Medtronic plc File Communication Regarding Business CombinationIncreased competition or market share shifts in continuous glucose monitoring (CGM) and insulin delivery systems.watch3-12m0.30
    2026-09-14Medtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.second_order_competitive_landscapewatch3-12m0.30
    2026-09-01MiniMed Group, Inc. Raises Fiscal Year 2027 Organic Revenue Growth GuidanceCompetitive dynamics and market share in the continuous glucose monitoring (CGM) market. Strong performance by a competitor could indicate a growing market but also increased competition.mixed1-3m0.40

    Continue this research

    Build your DexCom, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the DXCM entity page →

    Research DexCom, Inc. · $399/mo